Nano Precision Medical

About Nano Precision Medical

Nano Precision Medical, founded in 2009 by Adam Mendelsohn, Kayte Fischer, and Lily Peng, is a biopharmaceutical company that has developed a proprietary drug delivery system. The founders, who met as graduate students at the University of California, San Francisco, leveraged their bioengineering backgrounds to create a novel solution for the long-term management of chronic diseases.

The company's core technology is the NanoPortal, a subdermal implant about the size of a grain of rice. This implant is designed to provide continuous and consistent drug delivery for a year or more, offering an alternative to frequent injections for patients with conditions like diabetes and obesity. The NanoPortal system consists of a titanium capsule containing the drug and a nanoporous membrane that controls the drug's release rate. This approach aims to improve patient compliance and therapeutic outcomes by maintaining stable drug levels in the body.

Nano Precision Medical's business model focuses on developing and commercializing its drug implant portfolio. The company collaborates with pharmaceutical partners to load their proprietary drugs into the NanoPortal system. In a significant milestone, Nano Precision Medical merged with Second Sight Medical Products, which led to the formation of Vivani Medical. This merger provided the necessary capital and public market access to advance the clinical development of their lead product, a GLP-1 implant for the treatment of type 2 diabetes.